Pacira Pharmaceuticals Inc (PCRX)
Debt-to-assets ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | 513,796 | 655,823 | 674,530 | 313,030 | 306,045 |
| Total assets | US$ in thousands | 1,574,390 | 1,681,200 | 2,075,350 | 1,274,510 | 831,065 |
| Debt-to-assets ratio | 0.33 | 0.39 | 0.33 | 0.25 | 0.37 |
December 31, 2023 calculation
Debt-to-assets ratio = Long-term debt ÷ Total assets
= $513,796K ÷ $1,574,390K
= 0.33
The debt-to-assets ratio of Pacira BioSciences Inc has fluctuated over the past five years. In 2023, the ratio decreased to 0.33 from 0.41 in 2022, indicating that the company has reduced its reliance on debt in relation to its total assets. This improvement suggests a stronger financial position and potentially lower financial risk.
Comparing to 2021 when the ratio was 0.51, the significant reduction in debt-to-assets ratio shows a positive trend towards a more conservative capital structure. However, it is worth noting that in 2020 and 2019, the ratio was 0.36 and 0.37 respectively, which were lower than the recent value of 0.33. This suggests that the company had previously maintained relatively lower levels of debt in proportion to its assets before increasing it in 2021.
Overall, the decreasing trend in the debt-to-assets ratio from 2021 to 2023 indicates that Pacira BioSciences Inc has been managing its debt levels effectively, potentially improving its financial stability and liquidity position over the years.
Peer comparison
Dec 31, 2023